| |
|
|
|
Proqr Therapeutics  
|
|
5.21 -0.03 (-0.01%) |
09-22 16:00 |
|
Open: |
5.19 |
Pre close: |
5.24 |
Target:
|
6.75
|
|
High: |
5.2542 |
Low: |
5.075 |
Resistance:
|
5.78
6.38
|
|
Volume: |
74,268 |
Market Cap: |
261M |
Support:
|
4.81
4.00
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
5.33
 |
MACD |
MACD(12,26):
|
-0.01 |
|
MA(20): |
5.34 |
Signal(12,26,9): |
-0.01 |
|
MA(100): |
5.40  |
Stochastic Oscillator |
%K(14,3):
|
32.47 |
|
MA(250): |
6.55 |
%D(3): |
36.23 |
|
Average Volume(K) |
3-Month: |
14898
|
52-Week |
High:
|
10.98 |
|
10-Days: |
9267 |
Low: |
4.46 |
|
RSI |
RSI(14):
|
47.67 |
Change(%): |
-15.1 |
|
Financials, Statistics and Valuation |
|
EPS |
-1.310 |
Return on Equity (ttm) |
-68.0 |
Shares Out. (M) |
50.14 |
|
EPS Est. Current Year |
-2.110 |
Return on Assets (ttm) |
-40.2 |
Shares Float (M) |
36.85 |
|
EPS Est. Next Year |
-1.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
8.56 |
|
EPS Est. Next Quarter |
-0.520 |
Qtrly Rev. Growth |
-51.3 |
% Held by Institutions |
74.08 |
|
Forward EPS |
-1.241 |
Gross Profit (p.s.) |
0.038 |
Shares Short (K) |
688 |
|
Book Value (p.s.) |
3.090 |
EBITDA (p.s.) |
0.000 |
P/E |
-3.98 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
1.69 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
0.00 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
0.00 |
P/CF |
0.00 |
|
|
|
|
|
|
